Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
McKinsey
Chinese Patent Office
Harvard Business School
Moodys
Chubb
QuintilesIMS
Cipla
Julphar

Generated: July 16, 2018

DrugPatentWatch Database Preview

ORBACTIV Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Orbactiv patents expire, and when can generic versions of Orbactiv launch?

Orbactiv is a drug marketed by Melinta Therap and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-five patent family members in sixteen countries.

The generic ingredient in ORBACTIV is oritavancin diphosphate. Two suppliers are listed for this compound. Additional details are available on the oritavancin diphosphate profile page.
Summary for ORBACTIV
International Patents:35
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 13
Clinical Trials: 5
DailyMed Link:ORBACTIV at DailyMed
Drug patent expirations by year for ORBACTIV
Generic Entry Opportunity Date for ORBACTIV
Generic Entry Date for ORBACTIV*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
NDA:
Dosage::
POWDER;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for ORBACTIV
(4''R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin phosphate(1:2)
(4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin phosphate(1:2) (salt)
(4'R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3)'-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin phosphate (1:2) (salt)
(4'R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3)'-(p-(p-chlorophenyl)benzyl)vancomycin phosphate (1:2) (salt)
192564-14-0
AKOS030526689
CHEBI:83305
CS-5054
D05271
HY-B1831A
LY 333328 diphosphate
LY333328 diphosphate
Orbactiv (TN)
Oritavancin (diphosphate)
oritavancin bisphosphate
Oritavancin diphosphate
Oritavancin diphosphate (USAN)
Oritavancin diphosphate [USAN]
oritavancin phosphate
PWTROOMOPLCZHB-BHYQHFGMSA-N
UNII-VL1P93MKZN
VL1P93MKZN

US Patents and Regulatory Information for ORBACTIV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ORBACTIV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for ORBACTIV

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90041-7 Sweden ➤ Try a Free Trial PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323
16/040 Ireland ➤ Try a Free Trial PRODUCT NAME: ORITAVANCIN AND PHARMACEUTICAL SALTS THEREOF, E.G DIPHOSPHATE SALTS; REGISTRATION NO/DATE: EU/1/15/989 20150319
0834 Netherlands ➤ Try a Free Trial PRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323
/2016 Austria ➤ Try a Free Trial PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Argus Health
Covington
Accenture
Deloitte
Harvard Business School
Medtronic
Chinese Patent Office
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.